Postgenomic approaches to cholera vaccine development

References

• Kaper JB, Morris JG Jr, Levine MM. Cholera. Clin. Microbiol. Rev.8(1), 48–86 (1995).
   PubMed Web of Science ®Google Scholar
• Cholera vaccines. Wkly. Epidemiol. Rec.76(16), 117–124 (2001).
   PubMedGoogle Scholar
• Levine MM, Black RE, Clements ML et al. Duration of infection-derived immunity to cholera. J. Infect. Dis.143(6), 818–820 (1981).
   PubMed Web of Science ®Google Scholar
• Morris JG Jr, Losonsky GE, Johnson JA et al. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J. Infect. Dis.171(4), 903–908 (1995).
   PubMed Web of Science ®Google Scholar
• Levine MM, Nalin DR, Craig JP et al. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans. R. Soc. Trop. Med. Hyg.73(1), 3–9 (1979).
   PubMed Web of Science ®Google Scholar
• Freytag LC, Clements JD. Mucosal adjuvants. Vaccine23(15), 1804–1813 (2005).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Svennerholm AM. Mechanisms of disease and immunity in cholera: a review. J. Infect. Dis.136(Suppl.), S105–S112 (1977).
   Web of Science ®Google Scholar
• Attridge SR, Rowley D. Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae. J. Infect. Dis.148(5), 931–939 (1983).
   PubMed Web of Science ®Google Scholar
• Neoh SH, Rowley D. The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J. Infect. Dis.121(5), 505–513 (1970).
   PubMed Web of Science ®Google Scholar
• Saha D, LaRocque RC, Khan AI et al. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J. Infect. Dis.189(12), 2318–2322 (2004).
   PubMed Web of Science ®Google Scholar
• Ryan ET, Calderwood SB. Cholera vaccines. J. Travel Med.8(2), 82–91 (2001).
   PubMedGoogle Scholar
• Ali M, Emch M, von Seidlein L et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet366(9479), 44–49 (2005).
   PubMed Web of Science ®Google Scholar
• Clemens JD, Sack DA, Harris JR et al. Field trial of oral cholera vaccines in Bangladesh. Lancet2(8499), 124–127 (1986).
   PubMed Web of Science ®Google Scholar
• Clemens JD, Sack DA, Harris JR et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet335(8684), 270–273 (1990).
   PubMed Web of Science ®Google Scholar
• Ryan E T, Calderwood SB, Qadri F. Live attenuated oral cholera vaccines. Expert Rev. Vaccines (2006) (Submitted).
   Google Scholar
• Levine MM, Kaper JB, Herrington D et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet2(8609), 467–470 (1988).
   PubMed Web of Science ®Google Scholar
• Richie EE, Punjabi NH, Sidharta YY et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine18(22), 2399–2410 (2000).
   PubMed Web of Science ®Google Scholar
• Calain P, Chaine JP, Johnson E et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine22(19), 2444–2451 (2004).
   PubMed Web of Science ®Google Scholar
• Qadri F, Chowdhury MI, Faruque SM et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J. Infect. Dis.192(4), 573–579 (2005).
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science287(5459), 1816–1820 (2000).
   PubMed Web of Science ®Google Scholar
• de Jonge MI, Brosch R, Brodin P, Demangel C, Cole ST. Tuberculosis: from genome to vaccine. Expert Rev. Vaccines4(4), 541–551 (2005).
   PubMed Web of Science ®Google Scholar
• Maione D, Margarit I, Rinaudo CD et al. Identification of a universal group B streptococcus vaccine by multiple genome screen. Science309(5731), 148–150 (2005).
   PubMed Web of Science ®Google Scholar
• Heidelberg JF, Eisen JA, Nelson WC et al. DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature406(6795), 477–483 (2000).
   PubMed Web of Science ®Google Scholar
• Mazel D, Dychinco B, Webb VA, Davies J. A distinctive class of integron in the Vibrio cholerae genome. Science280(5363), 605–608 (1998).
   PubMed Web of Science ®Google Scholar
• Waldor MK, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science272(5270), 1910–1914 (1996).
   PubMed Web of Science ®Google Scholar
• Albert MJ, Siddique AK, Islam MS et al. Large outbreak of clinical cholera due to Vibrio cholerae non-O1 in Bangladesh. Lancet341(8846), 704 (1993).
   PubMed Web of Science ®Google Scholar
• Ramamurthy T, Garg S, Sharma R et al. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet341(8846), 703–704 (1993).
   PubMed Web of Science ®Google Scholar
• Comstock LE, Maneval D Jr, Panigrahi P et al. The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect. Immun.63(1), 317–323 (1995).
   PubMedGoogle Scholar
• Dziejman M, Balon E, Boyd D et al. Comparative genomic analysis of Vibrio cholerae: Genes that correlate with cholera endemic and pandemic disease. Proc. Natl Acad. Sci. USA99(3), 1556–1561 (2002).
   PubMedGoogle Scholar
• Dziejman M, Serruto D, Tam VC et al. Genomic characterization of non-O1, non-O139 Vibrio cholerae reveals genes for a type III secretion system. Proc. Natl Acad. Sci. USA102(9), 3465–3470 (2005).
   PubMedGoogle Scholar
• Chen CY, Wu KM, Chang YC et al. Comparative genome analysis of Vibrio vulnificus, a marine pathogen. Genome Res.13(12), 2577–2587 (2003).
   PubMed Web of Science ®Google Scholar
• Makino K, Oshima K, Kurokawa K et al. Genome sequence of Vibrio parahaemolyticus: a pathogenic mechanism distinct from that of V. cholerae. Lancet361(9359), 743–749 (2003).
   PubMed Web of Science ®Google Scholar
• Chiang SL, Mekalanos JJ, Holden DW. In vivo genetic analysis of bacterial virulence. Annu. Rev. Microbiol.53, 129–154 (1999).
   PubMed Web of Science ®Google Scholar
• Angelichio MJ, Camilli A. In vivo expression technology. Infect. Immun.70(12), 6518–6523 (2002).
   PubMed Web of Science ®Google Scholar
• Camilli A, Beattie DT, Mekalanos JJ. Use of genetic recombination as a reporter of gene expression. Proc. Natl Acad. Sci. USA91(7), 2634–2638 (1994).
   PubMed Web of Science ®Google Scholar
• Camilli A, Mekalanos JJ. Use of recombinase gene fusions to identify Vibrio cholerae genes induced during infection. Mol. Microbiol.18(4), 671–683 (1995).
   PubMed Web of Science ®Google Scholar
• Osorio CG, Crawford JA, Michalski J et al. Second-generation recombination-based in vivo expression technology for large-scale screening for Vibrio cholerae genes induced during infection of the mouse small intestine. Infect. Immun.73(2), 972–980 (2005).
   PubMed Web of Science ®Google Scholar
• Chiang SL, Mekalanos JJ. Use of signature-tagged transposon mutagenesis to identify Vibrio cholerae genes critical for colonization. Mol. Microbiol.27(4), 797–805 (1998).
   PubMed Web of Science ®Google Scholar
• Herrington DA, Hall RH, Losonsky G et al. Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J. Exp. Med.168(4), 1487–1492 (1988).
   PubMed Web of Science ®Google Scholar
• Taylor RK, Miller VL, Furlong DB, Mekalanos JJ. Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc. Natl Acad. Sci. USA84(9), 2833–2837 (1987).
   PubMed Web of Science ®Google Scholar
• Merrell DS, Hava DL, Camilli A. Identification of novel factors involved in colonization and acid tolerance of Vibrio cholerae. Mol. Microbiol.43(6), 1471–1491 (2002).
   PubMedGoogle Scholar
• Handfield M, Brady LJ, Progulske-Fox A, Hillman JD. IVIAT: a novel method to identify microbial genes expressed specifically during human infections. Trends Microbiol.8(7), 336–339 (2000).
   PubMed Web of Science ®Google Scholar
• Rollins SM, Peppercorn A, Hang L et al. In vivo induced antigen technology (IVIAT). Cell. Microbiol. 7(1), 1–9 (2005).
   Google Scholar
• Deb DK, Dahiya P, Srivastava KK, Srivastava R, Srivastava BS. Selective identification of new therapeutic targets of Mycobacterium tuberculosis by IVIAT approach. Tuberculosis (Edinb.)82(4–5), 175–182 (2002).
   PubMedGoogle Scholar
• Kim YR, Lee SE, Kim CM et al. Characterization and pathogenic significance of Vibrio vulnificus antigens preferentially expressed in septicemic patients. Infect. Immun.71(10), 5461–5471 (2003).
   PubMedGoogle Scholar
• John M, Kudva IT, Griffin RW et al. Use of in vivo-induced antigen technology for identification of Escherichia coli O157:H7 proteins expressed during human infection. Infect. Immun.73(5), 2665–2679 (2005).
   PubMed Web of Science ®Google Scholar
• Harris JB, Baresch-Bernal A, Rollins SM et al. Identification of in vivo-induced bacterial protein antigens during human infection with Salmonella enterica serovar typhi. (Submitted).
   Google Scholar
• Hang L, John M, Asaduzzaman M et al. Use of in vivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection with Vibrio cholerae.Proc. Natl Acad. Sci. USA100(14), 8508–8513 (2003).
   PubMed Web of Science ®Google Scholar
• Hall RH, Losonsky G, Silveira AP et al. Immunogenicity of Vibrio cholerae O1 toxin-coregulated pili in experimental and clinical cholera. Infect. Immun.59(7), 2508–2512 (1991).
   PubMed Web of Science ®Google Scholar
• Asaduzzaman M, Ryan ET, John M et al. The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139. Infect. Immun.72(8), 4448–4454 (2004).
   PubMed Web of Science ®Google Scholar
• Xu Q, Dziejman M, Mekalanos JJ. Determination of the transcriptome of Vibrio cholerae during intraintestinal growth and midexponential phase in vitro. Proc. Natl Acad. Sci. USA100(3), 1286–1291 (2003).
   PubMed Web of Science ®Google Scholar
• Merrell DS, Butler SM, Qadri F et al. Host-induced epidemic spread of the cholera bacterium. Nature417(6889), 642–645 (2002).
   PubMed Web of Science ®Google Scholar
• Bina J, Zhu J, Dziejman M et al. ToxR regulon of Vibrio cholerae and its expression in vibrios shed by cholera patients. Proc. Natl Acad. Sci. USA100(5), 2801–2806 (2003).
   PubMed Web of Science ®Google Scholar
• Lee SH, Hava DL, Waldor MK, Camilli A. Regulation and temporal expression patterns of Vibrio cholerae virulence genes during infection. Cell99(6), 625–634 (1999).
   PubMed Web of Science ®Google Scholar
• LaRocque RC, Harris JB, Dziejman M et al. Transcriptional profiling of Vibrio cholerae recovered directly from patient specimens during early and late stages of human infection. Infect. Immun.73(8), 4488–4493 (2005).
   PubMedGoogle Scholar
• Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet363(9404), 223–233 (2004).
   PubMed Web of Science ®Google Scholar
• Guerrant RL, Carneiro-Filho BA, Dillingham RA. Cholera, diarrhea, and oral rehydration therapy: triumph and indictment. Clin. Infect. Dis.37(3), 398–405 (2003).
   PubMed Web of Science ®Google Scholar
• Cavailler P, Lucas M, Perroud V et al. Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique. Vaccine (2005) (In press).
   PubMedGoogle Scholar
• Albert MJ, Qadri F, Wahed MA et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J. Infect. Dis.187(6), 909–913 (2003).
   PubMed Web of Science ®Google Scholar
• Karlsen TH, Sommerfelt H, Klomstad S et al. Intestinal and systemic immune responses to an oral cholera toxoid B subunit whole-cell vaccine administered during zinc supplementation. Infect. Immun.71(7), 3909–3913 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper PJ, Chico ME, Losonsky G et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J. Infect. Dis.182(4), 1199–1206 (2000).
   PubMed Web of Science ®Google Scholar
• Lagos R, Fasano A, Wasserman SS et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis.180(5), 1709–1712 (1999).
   PubMed Web of Science ®Google Scholar
• Qadri F, Bhuiyan TR, Dutta KK et al. Acute dehydrating disease cause by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut. Gut53, 62–69 (2004).
   PubMed Web of Science ®Google Scholar
• Harris JB, Khan AI, LaRocque RC et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect. Immun.73(11), 7422–7427 (2005).
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature409(6822), 860–921 (2001).
   PubMed Web of Science ®Google Scholar
• Stokes NR, Zhou X, Meltzer SJ, Kaper JB. Transcriptional responses of intestinal epithelial cells to infection with Vibrio cholerae. Infect. Immun.72(7), 4240–4248 (2004).
   PubMed Web of Science ®Google Scholar
• Patterson SD, Aebersold RH. Proteomics: The first decade and beyond. Nat. Genet.33(Suppl.), 311–323 (2003).
   PubMed Web of Science ®Google Scholar
• Fortune SM, Jaeger A, Sarracino DA et al. Mutually dependent secretion of proteins required for mycobacterial virulence. Proc. Natl Acad. Sci. USA102(30), 10676–10681 (2005).
   PubMed Web of Science ®Google Scholar
• Davies DH, Liang X, Hernandez JE et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl Acad. Sci. USA102(3), 547–552 (2005).
   PubMed Web of Science ®Google Scholar
• Chang HS, Sack DA. Development of a novel in vitro assay (ALS assay) for evaluation of vaccine-induced antibody secretion from circulating mucosal lymphocytes. Clin. Diagn. Lab. Immunol.8(3), 482–488 (2001).
   PubMedGoogle Scholar
• Qadri F, Ryan ET, Faruque AS et al. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: Comparison to antibody-secreting cell responses and other immunological markers. Infect. Immun.71(8), 4808–4814 (2003).
   PubMed Web of Science ®Google Scholar